Log in

LON:RENX - Renalytix Ai Share Price, Forecast & News

GBX 345
0.00 (0.00 %)
(As of 02/21/2020 02:27 AM ET)
Today's Range
Now: GBX 345
50-Day Range
MA: GBX 347.94
52-Week Range
Now: GBX 345
Volume2,381 shs
Average VolumeN/A
Market Capitalization£204.99 million
P/E RatioN/A
Dividend YieldN/A
Renalytix AI plc develops artificial intelligence (AI) enabled clinical decision support solutions for kidney disease. It is developing KidneyIntelX, an AI-enabled, clinical-laboratory based solution that supports physician decision making by improving identification, prediction, and risk stratification of patients with kidney disease. The company is based in Cardiff, the United Kingdom. Renalytix AI plc (AIM:RENX) operates independently of EKF Diagnostics Holdings plc as of November 2, 2018.

Industry, Sector and Symbol

Industry Diagnostics & Research



Sales & Book Value

Annual SalesN/A
Cash FlowGBX 15.60 per share
Book ValueGBX 52.30 per share



Market Cap£204.99 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RENX News and Ratings via Email

Sign-up to receive the latest news and ratings for RENX and its competitors with MarketBeat's FREE daily newsletter.

Renalytix Ai (LON:RENX) Frequently Asked Questions

What is Renalytix Ai's stock symbol?

Renalytix Ai trades on the London Stock Exchange (LON) under the ticker symbol "RENX."

Has Renalytix Ai been receiving favorable news coverage?

Media stories about RENX stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Renalytix Ai earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Renalytix Ai.

Who are some of Renalytix Ai's key competitors?

Who are Renalytix Ai's key executives?

Renalytix Ai's management team includes the folowing people:
  • Mr. James R. McCullough, CEO & Director (Age 51)
  • Mr. O. James Sterling III, Chief Financial Officer
  • Dr. Sally Bowden, Chief Operating Officer
  • Fergus Fleming, CTO & Director
  • Salim Hamir, Company Sec.

How do I buy shares of Renalytix Ai?

Shares of RENX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Renalytix Ai's stock price today?

One share of RENX stock can currently be purchased for approximately GBX 345.

How big of a company is Renalytix Ai?

Renalytix Ai has a market capitalization of £204.99 million. View Additional Information About Renalytix Ai.

What is Renalytix Ai's official website?

The official website for Renalytix Ai is http://www.renalytixai.com/.

MarketBeat Community Rating for Renalytix Ai (LON RENX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  13 (Vote Underperform)
Total Votes:  34
MarketBeat's community ratings are surveys of what our community members think about Renalytix Ai and other stocks. Vote "Outperform" if you believe RENX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RENX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel